CN103494213A - Preparation method of fat-fighting low-calorie full-nutrition meal replacement preparation - Google Patents
Preparation method of fat-fighting low-calorie full-nutrition meal replacement preparation Download PDFInfo
- Publication number
- CN103494213A CN103494213A CN201310449384.0A CN201310449384A CN103494213A CN 103494213 A CN103494213 A CN 103494213A CN 201310449384 A CN201310449384 A CN 201310449384A CN 103494213 A CN103494213 A CN 103494213A
- Authority
- CN
- China
- Prior art keywords
- preparation
- meal
- fat
- calories
- low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000012054 meals Nutrition 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 45
- CAXNYFPECZCGFK-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylacetonitrile Chemical compound C=1C=CC=NC=1C(C#N)C1=CC=CC=C1 CAXNYFPECZCGFK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 22
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 22
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 22
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 22
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 22
- 239000011707 mineral Substances 0.000 claims abstract description 22
- 235000009566 rice Nutrition 0.000 claims abstract description 22
- 239000011782 vitamin Substances 0.000 claims abstract description 22
- 229940088594 vitamin Drugs 0.000 claims abstract description 22
- 235000013343 vitamin Nutrition 0.000 claims abstract description 22
- 229930003231 vitamin Natural products 0.000 claims abstract description 22
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 22
- 230000035764 nutrition Effects 0.000 claims description 29
- 235000016709 nutrition Nutrition 0.000 claims description 29
- 241000219051 Fagopyrum Species 0.000 claims description 21
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 21
- 241000209094 Oryza Species 0.000 claims description 21
- 235000019486 Sunflower oil Nutrition 0.000 claims description 21
- 239000005862 Whey Substances 0.000 claims description 21
- 102000007544 Whey Proteins Human genes 0.000 claims description 21
- 108010046377 Whey Proteins Proteins 0.000 claims description 21
- 239000002600 sunflower oil Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 12
- 238000012856 packing Methods 0.000 claims description 7
- 238000010304 firing Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 8
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 7
- 230000036772 blood pressure Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 235000003642 hunger Nutrition 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- 235000008085 high protein diet Nutrition 0.000 abstract description 2
- 230000003908 liver function Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract 3
- 102000004407 Lactalbumin Human genes 0.000 abstract 1
- 108090000942 Lactalbumin Proteins 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 235000001916 dieting Nutrition 0.000 abstract 1
- 230000037228 dieting effect Effects 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 239000002417 nutraceutical Substances 0.000 abstract 1
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000035807 sensation Effects 0.000 abstract 1
- 235000020238 sunflower seed Nutrition 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 16
- 230000037396 body weight Effects 0.000 description 15
- 238000002485 combustion reaction Methods 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000011160 research Methods 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 206010063659 Aversion Diseases 0.000 description 7
- 235000020852 very low calorie diet Nutrition 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 208000019914 Mental Fatigue Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- -1 gamma-glutamyl amine Chemical class 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 230000000858 peroxisomal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000000157 fatty acyl carnitine group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 150000002520 isoleucines Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 238000010248 power generation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a preparation method of a fat-fighting low-calorie full-nutrition meal replacement preparation. The fat-fighting low-calorie full-nutrition meal replacement preparation is prepared from L-carnitine and common nutraceutical bulk pharmaceutical chemicals such as maltodextrin, rice meal, corn meal, soyabean protein powder, lactalbumin powder, sunflower seed oil, mineral substance mixtures, and vitamin mixtures, wherein the ratio of the L-carnitine is 1-6 percent. The L-carnitine has the function of improving the glucolipid metabolism, and an extremely-low-calorie high-protein diet has the functions of promoting the fat hydrolysis, lightening the hunger sensation, improving the lean body mass proportion and the like. Clinical and trial studies indicate that the fat-fighting low-calorie full-nutrition meal replacement preparation is accurate in treatment effect, is capable of rapidly reducing the weight within a short time, reducing the blood pressure, and improving the blood sugar, blood fat insulin sensitivity and liver functions, has a good prevention function on high blood pressure, diabetes and coronary heart disease, is capable of reducing adverse reaction in the dieting process and improving the tolerance of a human body to hunger, and has a good application prospect.
Description
Technical field
The present invention relates to the food formulation field, especially relate to a kind of preparation method of fat full nutrition low in calories for the meal preparation of firing.
Background technology
Epidemiological study in recent years shows, the illness rate of overweight/obesity raises year by year, as the independent hazard factor of the angiocardiopathies such as atherosclerotic, hypertension and coronary heart disease, genesis of itself and blood pressure rising, IGT, hyperinsulinemia and diabetes B etc. is closely related.And many studies have shown that, the about 5%-10% of Body weight loss left and right, the diseases such as hypertension, hyperlipidemia and endomorphy type non-insulin-depending type diabetes B can obtain reverse in various degree, can effectively reduce the angiocardiopathy occurrence risk.
Studies have shown that at present, reducing energy intake has reducing blood pressure, improves insulin sensitivity, reduces blood sugar, improves sugar tolerance, reduce inflammation reaction, alleviate oxidative stress, reduce the effects such as Peroxidative damage such as protein, DNA and lipid, can antiatherosclerosis, improve immunologic function and delay senility, thereby the risk that effectively angiocardiopathy preventing occurs.
High protein very low calorie diet (high protein very low calorie diet) can promote fat splitting, has and loses weight, and reduces blood pressure, improves blood lipid level, alleviates the curative effects such as fatty liver and increase insulin sensitivity.But in the process of strictly keeping on a diet, that the patient is prone to is weak, aversion to cold, lassitude and the under-supply performance of dizzy homenergic, and moreover, in the process of strictly keeping on a diet, Body weight loss shows as first quick and back slow; And, along with further research is found, longer time-histories very low calorie diet causes muscular tissue Mitochondria speed to descend, cause the power generation deficiency, thereby occur that weak, chilly, lassitude and the metabolic rate such as dizzy lowly show.
In sum, the discomforts such as weak, the aversion to cold occurred in the very low calorie diet process, dizziness and Body weight loss are slow reaction is to reduce closely related with mitochondrial function, develop the combustion fat full nutrition low in calories of a kind of better curative effect on obesity and low bad reaction for the meal preparation for this reason, for controlling body weight, there is good exploitation and application prospect.
Summary of the invention
In order to improve the slimming result for the treatment of of very low calorie diet, reduce simultaneously in strict diet control process, very easily occur weak, the incidence of the uncomfortable reaction such as aversion to cold and lassitude, according to domestic and international latest Progress, the characteristics such as carnitine shortage easily appear under the diet structure in conjunction with compatriots' prepared food and higher proportions of carbohydrate simultaneously, we research and develop the preparation method of the combustion fat that contains l-cn full nutrition low in calories for the meal preparation, research is found, in the diet control process, weak, the uncomfortable reaction such as aversion to cold and lassitude significantly reduces, Body weight loss is obvious simultaneously, without obvious thin soma, lose.
L-cn, be called again levocarnitine, DL-carnitine chloride, and its chemical name is β hydroxyl-γ-trimethyl ammonium butyrate, and its structural formula is that molecular formula is C7H15NO3, and molecular weight is 161.20, and modern study finds that its concrete physiological action is as follows:
As carrier with the fatty acyl carnitine form, LCFA is transported to from mitochondrial membrane to mitochondrial inner membrane and carries out beta oxidation, produce acetyl coenzyme A, enter tricarboxylic acid cycle, produce power.
2. the toxic products of fatty acid oxidation is eliminated to (long-chain fat coacetylase) in mitochondria; regulate free coacetylase and acidylate coacetylase; can effectively promote the oxidation of acetoacetate; contribute to intracellular metabolism; reduce ketoplasia; simultaneously can effectively alleviate fatty acid metabolism intermediate product (long-chain acyl, ceramide) to the inhibitory action of Mitochondria, alleviate keep on a diet due to metabolic rate descend.
3. participate in the oxidation of aliphatic acid at peroxidating corpusculum (Peroxisomal), when taking blood lipid-lowering medicine, this effect becomes and is even more important, because aliphatic acid increases by 10 to 20 times in the oxidation meeting of Peroxisomal in this case.
4. participate in the transportation of branched-chain amino acid as metabolites such as leucine, isoleucines, thereby be conducive to these amino acid whose eubolisms.
According to domestic and international current research, find, the high protein low caloric diet has following benefit for body weight control: 1. hyperaminoacidemia stimulates glucagon secretion, promotes fat splitting.
2. protein obviously delays gastric emptying, produces strong satiety, alleviates hunger.
3. high protein diet, reduce thin body protein and lose, and improves thin soma ratio.
In sum, from l-cn physiological action and modern study progress, in conjunction with strictly keeping on a diet down, weak, the aversion to cold be prone in body metabolism aliphatic acid process and the under-supply performance of lassitude homenergic, studies have shown that in the high protein very low calorie diet and add l-cn, and a kind of combustion fat full nutrition low in calories of developing is for the meal preparation, can effectively reduce weak, aversion to cold and the uncomfortable reaction such as dizzy, simultaneously, more be conducive to body weight control, the bounce-back of prevention body weight.
The present invention is prepared from by the bulk drug of calculating by mass percentage following weight parts:
Maltodextrin 20～30%, rice meal 5～15%, buckwheat 5～15%, soyabean protein powder 15～30%, PURE WHEY 10%～20%, sunflower oil 5～10%, mineral mixture 1.5～2.0%, vitamin mixtures 0.2～0.5%, l-cn 1-6%.
The weight portion proportion optimization of above-mentioned raw materials medicine:
Maltodextrin 30%, rice meal 5%, buckwheat 15%, soyabean protein powder 25%, PURE WHEY 15%, sunflower oil 6%, mineral mixture 1.5%, vitamin mixtures 0.5%, l-cn 2%.
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Maltodextrin 24%, rice meal 13%, buckwheat 10%, soyabean protein powder 24%, PURE WHEY 16%, sunflower oil 5%, mineral mixture 1.8%, vitamin mixtures 0.2%, l-cn 1%.
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Maltodextrin 26%, rice meal 7%, buckwheat 12%, soyabean protein powder 18%, PURE WHEY 20%, sunflower oil 10%, mineral mixture 1.6%, vitamin mixtures 0.4%, l-cn 5%.
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Maltodextrin 23%, rice meal 14%, buckwheat 8%, soyabean protein powder 30%, PURE WHEY 13%, sunflower oil 8.8%, mineral mixture 2.0%, vitamin mixtures 0.2%, l-cn 4%.
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Maltodextrin 25%, rice meal 11%, buckwheat 14%, soyabean protein powder 15%, PURE WHEY 18%, sunflower oil 9.5%, mineral mixture 1.2%, vitamin mixtures 0.3%, l-cn 6%.
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Maltodextrin 28%, rice meal 15%, buckwheat 7%, soyabean protein powder 27%, PURE WHEY 10%, sunflower oil 8%, mineral mixture 1.5%, vitamin mixtures 0.5%, l-cn 3%.
The accompanying drawing explanation
Accompanying drawing is the preparation method flow chart of combustion fat full nutrition low in calories for the meal preparation.
The specific embodiment
Below in conjunction with accompanying drawing, this novel invention is further illustrated.
As shown in the figure, pulvis preparation method of the present invention is maltodextrin, mineral mixture, vitamin mixtures, and two dimension mixes in advance for the first time; Add and use l-cn, row two dimension for the second time mixes in advance; Then add rice meal, buckwheat, soyabean protein powder, PURE WHEY, the capable efficient three-dimensional hybrid of sunflower oil.Sieve, packing, obtain pulvis of the present invention.
Experimental example: the clinical trial data of the medical food of the present invention
For the curative effect of fat full nutrition low in calories for the meal preparation fired in checking the present invention, we take random, single blind, the parallel control method by 1:1, complete the medical food associating of the present invention EA and use patient's 120 examples, combustion fat generation low in calories meal (l-cn group) 60 examples, conventional generation meal group low in calories (control group) 60 examples.L-cn group adverse reaction rate approximately 12%, and control group adverse reaction rate approximately 27%, Epidemiological Analysis by statistics, between two groups, clinical efficacy has significant difference, uncomfortable significant reaction occurs lower than control group in the l-cn group, and l-cn group bad reaction generation symptom is slight, end test without 1 example, control group occurs that the aobvious weak person of the 4 routine systems of Himdu logic ends test.
(1) inclusive criteria: 1, age 18-70 year; 2, body mass index>=28kg/m
2; 3, signature Informed Consent Form.
(2) exclusion standard: gestation, lactation or menstrual period women; The heart, liver, renal function are undesired; Malignant tumour and inpatient with haematological diseases; The active tuberculosis patient; The ulcer patient of serious gastrorrhagia; Diabetes; Take impact sugar, fat metabolic drug person; Can not partner treatment, the poor person of compliance; Do not sign Informed Consent Form.
(3) research approach
Research approach is followed the Ethical Demand of Declaration of Helsinki in 1975, and obtaining No.1 Hospital Affiliated to Zhongshan Univ.'s ethics can ratify.This programme enters altogether group 120 examples and suffers from the experimenter, and all experimenters all sign Informed Consent Form; Random according to 1:1, single blind, contrast principle is divided into l-cn group and control group, all experimenters take in heat about 600kcal/d altogether every day, comprise that the full nutrition low in calories of combustion fat is for meal preparation (200Kcal/ bag, 1 bag/time, every day three times) (carbohydrate: protein: fat=50:43:6) and vegetable juice low in calories, totally 6 weeks time.Keep during this time the daily exercise amount, do not carry out strong physical sport, can be taken a walk, climb the mountain, swim and wait by bike motion, taboo basketball, football, hurry up and the strong physical sport such as long-distance running, within 2 weeks, follow up a case by regular visits to 1 time.
(4) observation index
Ordinary circumstance: body weight, blood pressure, heart rate, waistline, hip circumference, waist-to-hipratio
Subjective index: observe experimenter's fatigue exponent, by Wessely and Powell mark standards of grading (seeing attached 1);
Blood testing: liver zymetology, blood sugar, four items of blood lipid tests, blood uric acid, insulin level and hs-CRP (Hs-CRP) and free fatty (Free fatty acid, FFA).The whole blood index is measured by clinical laboratory of No.1 Hospital Affiliated to Zhongshan Univ. bio-chemical detector.
Attached 1:
A. physical fatigue scoring
B. mental fatigue scoring
C. tired severity scale (The Fatigue Severity Scale, FSS):
* 1=disagrees with very much, and 7=agrees very much
Scoring<4 belongs to normal.
(4) statistical procedures and the summarization of data
After clinical testing finishes, all clinical datas carry out statistical analysis with SPSS software.Clinical total effects, clinical symptoms etc. after two groups of treatments are carried out to statistical analysis, comparison, and last objective evaluation the present invention coordinates curative effect and the security thereof of EA.
Statistical method: grouped data X
2check, relatively Wilcoxon rank test (correction) of two samples for ranked data, two sample means are relatively with t check or Wilcoxon rank test, before and after self relatively with paired t-test or Wilcoxon pairing rank test, all statistical checks all adopt two-sided test, and the P value is less than or equal to 0.05 and will be considered to checked difference statistical significance is arranged.
(5) result
1, physical data
This research has experimenter's 120 examples, according to the 1:1 principle, is divided at random combustion fat full nutrition low in calories for meal preparation (l-cn group) 60 examples and conventional generation low in calories preparation (control group) 60 examples of eating.
The 120 routine experimenters of this research, Epidemiological Analysis by statistics, the l-cn group mean age is 38 ± 15.3 (y), the control group mean age is 40 ± 16.4 (y), the age no difference of science of statistics; The l-cn group: the male/female ratio is 18/42, control group: the male/female ratio is 15/45; The equal no difference of science of statistics of body weight and BMI.
1 routine alopecia appears in the l-cn group, and 5 examples are slightly weak, 2 example diarrhoea, and 2 routine constipation, end test without 1 example; Control group 1 example diarrhoea, constipation 4 examples, 2 routine alopecias, 9 examples are obviously weak, and 4 examples are because of serious weak termination test.
2, ordinary circumstance relatively
As shown in table 1, after heat restriction in 6 weeks, 2 groups of body weight, body mass index, waistline, hip circumference, waist stern, blood pressures all significantly descend, with control group, compare, l-cn group experimenter body weight, body mass index and waist-to-hipratio all descend significantly, and the combustion fat full nutrition low in calories that l-cn is added in prompting has and significantly reduces the body weight effect for the meal preparation.
Table 1 liang group experimenter's ordinary circumstance
With the treatment before compare, * P value<0.05, * * P value<0.01, NS: no significant difference
3, combustion fat full nutrition low in calories for the meal preparation on glycometabolic impact
As shown in table 2, after heat restriction in 6 weeks, follow Body weight loss simultaneously, experimenter's blood sugar, insulin level all significantly reduce, insulin resistance improves obviously, with control group, compares, and l-cn group blood sugar, insulin level descend more remarkable, difference has statistical significance, points out novel high protein utmost point low-calorie nutrition powder have obvious reduction blood sugar and improve the insulin resistance texts.
4, combustion fat full nutrition low in calories for the meal preparation on lipometabolic impact
As shown in table 2, after heat restriction in 6 weeks, serum free fatty acid, cholesterol, triglycerides, LDL-C, glutamic-pyruvic transaminase and gamma-glutamyl amine transaminase level all significantly descend, and difference has significant difference, and hdl level all significantly raises; With control group, compare, l-cn group triglycerides, free fatty, glutamic-pyruvic transaminase and gamma-glutamyl amine transaminase level all significantly descend, difference has statistical significance, point out novel high protein utmost point low-calorie nutrition pulvis to there is the obvious fat metabolism that improves, promote fat splitting and alleviate the curative effect such as fatty liver.
5, combustion fat full nutrition low in calories impact on inflammation for the meal preparation
As shown in table 2, through heat restriction in 6 weeks, the hs-CRP level all significantly descended; With control group, compare, l-cn group hs-CRP level descends more remarkable, and difference has statistical significance.Point out novel high protein utmost point low-calorie nutrition pulvis to there is the reaction level of reducing inflammation, there is remarkable cardiovascular protection effect.
Table 2 blood parameters
With the treatment before compare, * * P value<0.01, NS: no significant difference
6, combustion fat full nutrition low in calories impact on fatigue exponent for the meal preparation
As shown in table 3, in 6 weeks heat limit procedure, l-cn group experimenter physical fatigue indexed performance is for first raising and descend afterwards, and control group experimenter physical fatigue indexed performance is for raising, with control group, compare, l-cn group experimenter physical fatigue index significantly reduces, and difference has statistical significance (P<0.001).
In 6 weeks heat limit procedure, along with time lengthening, the rear decline that first raises of l-cn group experimenter mental fatigue index, but still higher than level before treatment; With control group, compare, l-cn group experimenter mental fatigue index significantly reduces, and difference has statistical significance (P<0.001).
In 6 weeks heat limit procedure, the rear reduction that first raises of the tired order of severity of l-cn group experimenter, level difference not statistically significant (P=0.654) before treating after 6 weeks, the control group experimenter is along with the heat binding hours extends, the tired order of severity increases gradually, with level difference before treatment, statistical significance (P<0.001) is arranged.
The novel high protein utmost point low-calorie nutrition pulvis of this research prompting can effectively reduce the degree of fatigue occurred in the heat limit procedure, improves tolerance, alleviates uncomfortable reaction.
Table 3 fatigue exponent
7, therapeutic evaluation
Combustion fat full nutrition low in calories for meal preparation and conventional generation low in calories the preparation of eating compare, having the fat splitting of promotion loses weight, reduce blood sugar and insulin level, improve insulin resistance, reduce triglycerides, improve the significant curative effects such as fatty liver and reduction inflammatory reaction, meanwhile, can effectively prevent the weak symptom of fatigue occurred in the heat limit procedure, improve tolerance.
8, discuss
As everyone knows, heat restriction has antiatherosclerosis, improve immunologic function and the effect such as delay senility, but in the heat limit procedure, and that human body very easily occurs is weak, aversion to cold and the not enough performance of lassitude homenergic, greatly limits its clinical practice.
The present invention consists of high protein low-calorie nutrition powder and l-cn, it not only can reduce rapidly body weight in a short time, reduce blood pressure, improve blood sugar, blood fat, insulin sensitivity and liver function, reduce Analysis on Cardiovascular Risk Factors, diabetes, hypertension and coronary heart disease are had to good preventive and therapeutic action, and can improve the highest weak performance of incidence in the heat limit procedure, the raising crowd, to hungry tolerance, is conducive to clinical application.
Embodiment 1
Maltodextrin 30, mineral mixture 1.5, vitamin mixtures 0.5, two dimension mixes in advance for the first time; Add l-cn 2, row two dimension for the second time mixes in advance; Then add rice meal 5, buckwheat 15, soyabean protein powder 25, PURE WHEY 15, the efficient three-dimensional hybrid of sunflower oil 6 row.Sieve, packing, obtain pulvis of the present invention.
Embodiment 2
Maltodextrin 24, mineral mixture 1.8, vitamin mixtures 0.2, two dimension mixes in advance for the first time; Add l-cn 1, row two dimension for the second time mixes in advance; Then add rice meal 13, buckwheat 10, soyabean protein powder 24, PURE WHEY 16, the efficient three-dimensional hybrid of sunflower oil 5 row.Sieve, packing, obtain pulvis of the present invention.
Embodiment 3
Maltodextrin 26, mineral mixture 1.6, vitamin mixtures 0.4, two dimension mixes in advance for the first time; Add l-cn 5, row two dimension for the second time mixes in advance; Then add rice meal 7, buckwheat 12, soyabean protein powder 18, PURE WHEY 20, the efficient three-dimensional hybrid of sunflower oil 10 row.Sieve, packing, obtain pulvis of the present invention.
Embodiment 4
Maltodextrin 23, mineral mixture 2.0, vitamin mixtures 0.2, two dimension mixes in advance for the first time; Add l-cn 4, row two dimension for the second time mixes in advance; Then add rice meal 14, buckwheat 8, soyabean protein powder 30, PURE WHEY 13, the efficient three-dimensional hybrid of sunflower oil 8.8 row.Sieve, packing, obtain pulvis of the present invention.
Embodiment 5
Maltodextrin 25, mineral mixture 1.2, vitamin mixtures 0.3, two dimension mixes in advance for the first time; Add l-cn 6, row two dimension for the second time mixes in advance; Then add rice meal 11, buckwheat 14, soyabean protein powder 15, PURE WHEY 18, the efficient three-dimensional hybrid of sunflower oil 9.5 row.Sieve, packing, obtain pulvis of the present invention.
Claims (9)
1. one kind fires the preparation method of fat full nutrition low in calories for the meal preparation, it is characterized in that it is to be prepared from by the bulk drug of calculating by mass percentage following weight parts:
Maltodextrin 20～30%, rice meal 5～15%, buckwheat 5～15%, soyabean protein powder 15～30%, PURE WHEY 10%～20%, sunflower oil 5～10%, mineral mixture 1.5～2.0%, vitamin mixtures 0.2～0.5%, l-cn 1-6%.
According to claim 1 a kind of fire fat full nutrition low in calories for meal preparation the preparation method, it is characterized in that, the weight portion of following raw material medicaments is: maltodextrin 30%, rice meal 5%, buckwheat 15%, soyabean protein powder 25%, PURE WHEY 15%, sunflower oil 6%, mineral mixture 1.5%, vitamin mixtures 0.5%, l-cn 2%.
According to claim 1 a kind of fire fat full nutrition low in calories for meal preparation the preparation method, it is characterized in that, the weight portion of following raw material medicaments is: maltodextrin 24%, rice meal 13%, buckwheat 10%, soyabean protein powder 24%, PURE WHEY 16%, sunflower oil 5%, mineral mixture 1.8%, vitamin mixtures 0.2%, l-cn 1%.
According to claim 1 a kind of fire fat full nutrition low in calories for meal preparation the preparation method, it is characterized in that, the weight portion of following raw material medicaments is: maltodextrin 26%, rice meal 7%, buckwheat 12%, soyabean protein powder 18%, PURE WHEY 20%, sunflower oil 10%, mineral mixture 1.6%, vitamin mixtures 0.4%, l-cn 5%.
According to claim 1 a kind of fire fat full nutrition low in calories for meal preparation the preparation method, it is characterized in that, the weight portion of following raw material medicaments is: maltodextrin 23%, rice meal 14%, buckwheat 8%, soyabean protein powder 30%, PURE WHEY 13%, sunflower oil 8.8%, mineral mixture 2.0%, vitamin mixtures 0.2%, l-cn 4%.
According to claim 1 a kind of fire fat full nutrition low in calories for meal preparation the preparation method, it is characterized in that, the weight portion of following raw material medicaments is: maltodextrin 25%, rice meal 11%, buckwheat 14%, soyabean protein powder 15%, PURE WHEY 18%, sunflower oil 9.5%, mineral mixture 1.2%, vitamin mixtures 0.3%, l-cn 6%.
According to claim 1 a kind of fire fat full nutrition low in calories for meal preparation the preparation method, it is characterized in that, the weight portion of following raw material medicaments is: maltodextrin 28%, rice meal 15%, buckwheat 7%, soyabean protein powder 27%, PURE WHEY 10%, sunflower oil 8%, mineral mixture 1.5%, vitamin mixtures 0.5%, l-cn 3%.
8. according to the described a kind of preparation method of fat full nutrition low in calories for the meal preparation of firing of claim 1-7 any one, it is characterized in that: said preparation is pulvis.
9. a kind of preparation method of fat full nutrition low in calories for the meal preparation of firing according to claim 8, is characterized in that comprising the following steps: at first first adding the capable two dimension for the first time of maltodextrin, mineral mixture and vitamin mixtures to mix in advance; So secondly adding the capable two dimension for the second time of l-cn mixes in advance; The 3rd adds rice meal, buckwheat, soyabean protein powder, PURE WHEY, the capable efficient three-dimensional hybrid of sunflower oil; Finally sieve, packing, obtain pulvis of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310449384.0A CN103494213A (en) | 2013-09-26 | 2013-09-26 | Preparation method of fat-fighting low-calorie full-nutrition meal replacement preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310449384.0A CN103494213A (en) | 2013-09-26 | 2013-09-26 | Preparation method of fat-fighting low-calorie full-nutrition meal replacement preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103494213A true CN103494213A (en) | 2014-01-08 |
Family
ID=49859552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310449384.0A Pending CN103494213A (en) | 2013-09-26 | 2013-09-26 | Preparation method of fat-fighting low-calorie full-nutrition meal replacement preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103494213A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104351795A (en) * | 2014-12-01 | 2015-02-18 | 广东岭南职业技术学院 | Meal replacement powder for assisting blood pressure lowering and preparation method of meal replacement powder for assisting blood pressure lowering |
| CN105341923A (en) * | 2015-11-23 | 2016-02-24 | 黄山学院 | Selenium-enriched meal replacement food capable of reducing weight and preparation method of selenium-enriched meal replacement food |
| CN105533675A (en) * | 2015-11-14 | 2016-05-04 | 中山森谱生物科技有限公司 | Weight reducing protein powder and preparation method thereof |
| CN105661277A (en) * | 2016-01-05 | 2016-06-15 | 萧县佳洁面粉有限公司 | Special flour for bodybuilding and preparation technology of special flour |
| CN106722963A (en) * | 2017-01-10 | 2017-05-31 | 谢少韩 | A kind of vegetarian diet meal |
| EP3175718A4 (en) * | 2014-08-01 | 2017-12-20 | Bin Yang | Instant food with comprehensive nutrition |
| CN108095068A (en) * | 2017-11-30 | 2018-06-01 | 北京东方红航天生物技术股份有限公司 | The food compositions and its application method of control body weight |
| CN108244625A (en) * | 2018-01-11 | 2018-07-06 | 广州拜扬生物科技有限公司 | A kind of nutritional meal replacing food after bariatric surgery |
| CN109007840A (en) * | 2018-09-18 | 2018-12-18 | 广东雪芝康生物科技有限公司 | A kind of nutritive plant powder and preparation method thereof by adjusting gene reducing weight and blood fat |
| CN109259249A (en) * | 2018-09-20 | 2019-01-25 | 光谷迈德（武汉）慢性病研究院有限公司 | It is a kind of to prevent to improve hyperuricemia and the functional food of gout and its preparation method and application |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101194691A (en) * | 2007-11-26 | 2008-06-11 | 华东理工大学 | Low calorie foods of nutrition strengthening wheat plantule |
| KR20080088231A (en) * | 2007-03-29 | 2008-10-02 | (주)네오뉴트라 | Diet food and cup-shaped container |
| EP1982604A1 (en) * | 2007-04-20 | 2008-10-22 | Naturheilzentrum Allgäu | Dietary supplement for compensating for a lack of nutrients |
| RU2362323C2 (en) * | 2004-12-30 | 2009-07-27 | Хилл`С Пет Ньютришн, Инк. | Method of improving quality of life of growing animal and use of composition thereof |
| CN101524154A (en) * | 2009-04-07 | 2009-09-09 | 北京康比特体育科技股份有限公司 | Fat reducing food bar |
| CN102077949A (en) * | 2011-01-27 | 2011-06-01 | 北京康比特体育科技股份有限公司 | Diet meal replacement nutrition bar and preparation method thereof |
| CN102106498A (en) * | 2010-12-28 | 2011-06-29 | 北京康比特体育科技股份有限公司 | Weight losing meal-replacing powder |
| CN102228069A (en) * | 2011-06-21 | 2011-11-02 | 北京康比特体育科技股份有限公司 | Baking stick for weight-reducing fast food and preparation method thereof |
| CN102309010A (en) * | 2011-07-01 | 2012-01-11 | 海南椰国食品有限公司 | Bacterial cellulose weight-losing meal-substituting foodstuff |
| CN103238852A (en) * | 2013-06-04 | 2013-08-14 | 上海魅丽健康管理咨询有限公司 | Novel weight reducing meal replacement powder |
-
2013
- 2013-09-26 CN CN201310449384.0A patent/CN103494213A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2362323C2 (en) * | 2004-12-30 | 2009-07-27 | Хилл`С Пет Ньютришн, Инк. | Method of improving quality of life of growing animal and use of composition thereof |
| KR20080088231A (en) * | 2007-03-29 | 2008-10-02 | (주)네오뉴트라 | Diet food and cup-shaped container |
| EP1982604A1 (en) * | 2007-04-20 | 2008-10-22 | Naturheilzentrum Allgäu | Dietary supplement for compensating for a lack of nutrients |
| CN101194691A (en) * | 2007-11-26 | 2008-06-11 | 华东理工大学 | Low calorie foods of nutrition strengthening wheat plantule |
| CN101524154A (en) * | 2009-04-07 | 2009-09-09 | 北京康比特体育科技股份有限公司 | Fat reducing food bar |
| CN102106498A (en) * | 2010-12-28 | 2011-06-29 | 北京康比特体育科技股份有限公司 | Weight losing meal-replacing powder |
| CN102077949A (en) * | 2011-01-27 | 2011-06-01 | 北京康比特体育科技股份有限公司 | Diet meal replacement nutrition bar and preparation method thereof |
| CN102228069A (en) * | 2011-06-21 | 2011-11-02 | 北京康比特体育科技股份有限公司 | Baking stick for weight-reducing fast food and preparation method thereof |
| CN102309010A (en) * | 2011-07-01 | 2012-01-11 | 海南椰国食品有限公司 | Bacterial cellulose weight-losing meal-substituting foodstuff |
| CN103238852A (en) * | 2013-06-04 | 2013-08-14 | 上海魅丽健康管理咨询有限公司 | Novel weight reducing meal replacement powder |
Non-Patent Citations (2)
| Title |
|---|
| 王京钟等: "L-左旋肉碱对人体运动能力的影响", 《中国食品添加剂》, no. 05, 15 October 2003 (2003-10-15) * |
| 陈奇等: "瘦身谷物食品的研制及其功能评价", 《中国粮油学报》, no. 03, 25 May 2007 (2007-05-25) * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3175718A4 (en) * | 2014-08-01 | 2017-12-20 | Bin Yang | Instant food with comprehensive nutrition |
| CN104351795A (en) * | 2014-12-01 | 2015-02-18 | 广东岭南职业技术学院 | Meal replacement powder for assisting blood pressure lowering and preparation method of meal replacement powder for assisting blood pressure lowering |
| CN104351795B (en) * | 2014-12-01 | 2016-06-01 | 广东岭南职业技术学院 | A kind of aided blood pressure-lowering generation meal powder and its preparation method |
| CN105533675A (en) * | 2015-11-14 | 2016-05-04 | 中山森谱生物科技有限公司 | Weight reducing protein powder and preparation method thereof |
| CN105341923A (en) * | 2015-11-23 | 2016-02-24 | 黄山学院 | Selenium-enriched meal replacement food capable of reducing weight and preparation method of selenium-enriched meal replacement food |
| CN105661277A (en) * | 2016-01-05 | 2016-06-15 | 萧县佳洁面粉有限公司 | Special flour for bodybuilding and preparation technology of special flour |
| CN106722963A (en) * | 2017-01-10 | 2017-05-31 | 谢少韩 | A kind of vegetarian diet meal |
| CN108095068A (en) * | 2017-11-30 | 2018-06-01 | 北京东方红航天生物技术股份有限公司 | The food compositions and its application method of control body weight |
| CN108095068B (en) * | 2017-11-30 | 2020-10-27 | 北京东方红航天生物技术股份有限公司 | Food composition for weight management and method of use thereof |
| CN108244625A (en) * | 2018-01-11 | 2018-07-06 | 广州拜扬生物科技有限公司 | A kind of nutritional meal replacing food after bariatric surgery |
| CN109007840A (en) * | 2018-09-18 | 2018-12-18 | 广东雪芝康生物科技有限公司 | A kind of nutritive plant powder and preparation method thereof by adjusting gene reducing weight and blood fat |
| CN109259249A (en) * | 2018-09-20 | 2019-01-25 | 光谷迈德（武汉）慢性病研究院有限公司 | It is a kind of to prevent to improve hyperuricemia and the functional food of gout and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103494213A (en) | Preparation method of fat-fighting low-calorie full-nutrition meal replacement preparation | |
| Abazarfard et al. | The effect of almonds on anthropometric measurements and lipid profile in overweight and obese females in a weight reduction program: A randomized controlled clinical trial | |
| De Oliveira et al. | Weight loss associated with a daily intake of three apples or three pears among overweight women | |
| Jenkins et al. | Glycemic index: overview of implications in health and disease | |
| CN101455370B (en) | Energy rod | |
| Gobato et al. | Micronutrient and physiologic parameters before and 6 months after RYGB | |
| Wang et al. | Regular intake of white kidney beans extract (Phaseolus vulgaris L.) induces weight loss compared to placebo in obese human subjects | |
| BAHREINIAN et al. | Opinion: quantity and quality of carbohydrate intake in Iran: a target for nutritional intervention | |
| CN101297695A (en) | Stick-shaped nutrient health food for improving energy and preparation thereof | |
| Collene et al. | Effects of a nutritional supplement containing Salacia oblonga extract and insulinogenic amino acids on postprandial glycemia, insulinemia, and breath hydrogen responses in healthy adults | |
| CN104305206A (en) | Enteral nutrition preparation for fat-burning intervention on metabolic syndrome and application thereof | |
| US20210145915A1 (en) | Formulations for weight loss and methods of use | |
| CN105407740A (en) | Administration of a food composition product | |
| Roy et al. | Effect of nutritional intervention on malnutrition indicators in patients on haemodialysis | |
| Ta et al. | Effectiveness of Textured Soybean Protein on Blood Biochemistry in Vietnamese Type 2 Diabetes Mellitus Patients | |
| Radha et al. | Role of medicinal plant Salacia reticulata in the management of type II diabetic subjects | |
| Jaffari et al. | The effect of 8 weeks of carob supplementation and resistance training on lipid profile and irisin in obese men | |
| CN102224931B (en) | Composition assisting in reduction of blood sugar | |
| Trinidad et al. | Glycemic index of Sunfibre (Cyamoposis tetragonolobus. | |
| WO2013186233A1 (en) | Composition | |
| Silva et al. | Macronutrients and energy content of oral hospital diet prescribed to chronic kidney disease patients on conservative treatment. | |
| Altaher et al. | Effect of Ramadan Fasting on Anthropometric Measures and some Biochemical Parameters among Type2 Diabetic Patients in Gaza Governorate, Gaza Strip | |
| Shikora et al. | Nutrition and immunology: Clinician’s approach | |
| Iyer et al. | Impact of Amla (Embilica Officinalis) supplementation on the glycemic and lipidemic status of type 2 diabetic subjects | |
| CN102245037A (en) | A composition and a method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140108 |